CPHI
CHINA PHARMA HOLDINGS, INC.
-0.01 (-1.37%)0.72USD44.6K成交股數31.0M市值–本益比(近四季)7.9股價營收比-7.5%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 948K-8% | 984K-13% | 1.2M+11% | 756K-18% | 1.0M-25% | 1.1M-47% | 1.1M-39% | 925K-16% | 1.4M | 2.1M | 1.8M | 1.1M |
| 營業成本 | 865K | 698K | 1.1M | 816K | 1.1M | 1.3M | 1.6M | 1.9M | 1.7M | 2.2M | 2.0M | 1.2M |
| 毛利 | 84K-196% | 285K-310% | 151K-129% | −60K-94% | −87K-70% | −136K+72% | −520K+123% | −1.0M+592% | −290K | −79K | −233K | −147K |
| 毛利率 | 8.8% | 29.0% | 12.3% | -7.9% | -8.5% | -12.0% | -47.2% | -109.8% | -21.2% | -3.7% | -12.9% | -13.4% |
| 研發費用 | 19K | 84K | 190K | 40K | 21K | 30K | 88K | 164K | 31K | 148K | 46K | 24K |
| 銷售管理費用 | 1.4M | 1.2M | 1.1M | 425K | 441K | 507K | 345K | 92K | 488K | 690K | 246K | 112K |
| 營業利益 | −1.4M+120% | −1.1M+47% | −1.2M+11% | −628K-55% | −652K-29% | −759K-36% | −1.1M+52% | −1.4M+205% | −916K | −1.2M | −714K | −456K |
| 營業利益率 | -151.0% | -113.6% | -97.9% | -83.1% | -63.6% | -66.8% | -98.6% | -150.4% | -66.9% | -55.1% | -39.6% | -41.6% |
| 稅後淨利 | −1.5M+176% | −1.1M+46% | −1.2M+9% | −651K-55% | −528K-45% | −786K-36% | −1.1M+44% | −1.4M+143% | −956K | −1.2M | −778K | −593K |
| 淨利率 | -153.8% | -116.2% | -99.7% | -86.2% | -51.5% | -69.1% | -101.6% | -155.5% | -69.8% | -57.3% | -43.1% | -54.0% |
| 稀釋 EPS | -0.04-75% | -0.04-83% | -0.17-74% | -0.17-81% | -0.16-78% | -0.24+14% | -0.65+124% | -0.89+154% | -0.72 | -0.21 | -0.29 | -0.35 |
| 稀釋股數 | 40.5M | 25.6M | – | – | 3.2M | 3.3M | – | – | – | – | – | – |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 305K | 168K | 345K | 268K | 600K | 400K | 700K | 739K | 839K | 1.4M | 1.4M | 902K |
| 應收帳款 | 182K | 196K | 241K | 225K | 269K | 329K | 333K | 255K | – | 504K | 368K | 92K |
| 存貨 | 1.4M | 1.5M | 1.6M | 1.6M | 1.7M | 2.0M | 2.5M | 2.8M | – | 3.7M | 3.8M | 3.9M |
| 總資產 | 44.7M | 45.1M | 31.0M | 15.8M | 13.8M | 14.2M | 13.5M | 14.3M | – | 16.5M | 15.4M | 15.7M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 8.5M | 8.1M | 8.3M | 7.5M | 7.3M | 7.2M | 6.9M | 6.9M | – | 9.0M | 9.2M | 11.4M |
| 股東權益 | 36.2M | 37.0M | 22.7M | 8.3M | 6.5M | 7.0M | 6.5M | 7.4M | 8.3M | 7.5M | 6.1M | 4.4M |
| 負債比 | 19.1% | 18.0% | 26.6% | 47.4% | 53.1% | 51.0% | 51.5% | 48.1% | – | 54.7% | 60.2% | 72.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −55K-25% | – | – | – | −74K | – | – | −585K | – | – | – |
| 資本支出 | – | – | – | – | – | 58K | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | −132K | – | – | – | – | – | – |
| 折舊攤銷 | – | 981K | – | – | – | 329K | – | – | 734K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | -11.6% | – | – | – | – | – | – |
營收拆解 2021 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2021 年度 · 9.6M
| Domestic Pharmaceuticals | 9.6M | 100.0% | +5.6% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 4.1M | -8.5% | −3.2M | -76.9% | -0.74 | 89K |
| FY2024 | 4.5M | -35.4% | −4.7M | -104.6% | -2.71 | −444K |
| FY2023 | 7.0M | -13.5% | −3.1M | -43.9% | -0.91 | −711K |
| FY2022 | 8.1M | -15.9% | −4.0M | -49.0% | -3.78 | −812K |
| FY2021 | 9.6M | -11.3% | −3.4M | -35.3% | -0.74 | −688K |
| FY2020 | 10.9M | -0.5% | −2.9M | -26.4% | -0.07 | −910K |
| FY2019 | 10.9M | -11.4% | −20.7M | -189.5% | -0.48 | 472K |
| FY2018 | 12.3M | – | −10.8M | -87.2% | -0.25 | 1.8M |